Lara Dimick‐Santos

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

Arun J. Sanyal, Scott L. Friedman, Arthur J. McCullough et al. · Hepatology · 2014 · 347 citations · Full text

Medicine, Pathology, Pharmacology +17

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

Mohammad Shadab Siddiqui, Stephen A. Harrison, Manal F. Abdelmalek et al. · Hepatology · 2017 · 167 citations · Full text

Medicine, Internal Medicine, Clinical Research Regulation +13

Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration

Frank A. Anania, Lara Dimick‐Santos, Ruby Mehta et al. · Hepatology · 2020 · 51 citations

Medicine, Internal Medicine, Nutrition +16

Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum

Mazen Noureddin, Jean L. Chan, Katherine Barradas et al. · Gastroenterology · 2020 · 25 citations · Full text

Medicine, Internal Medicine, Clinical Trial Regulation +10

An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids

Sarah Kang, Allen Brinker, S. Christopher Jones et al. · Drug Safety · 2020 · 18 citations

Pharmacy, Pharmacotherapy, Toxicology +16